

**Iclusig**  
**Prior Authorization Request**

**Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-866-249-6155**

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155.** If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506**. For inquiries or questions related to the patient's eligibility, drug copy or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

**Patient's Name:** \_\_\_\_\_ **Date:** \_\_\_\_\_  
**Patient's ID:** \_\_\_\_\_ **Patient's Date of Birth:** \_\_\_\_\_  
**Physician's Name:** \_\_\_\_\_ **NPI#:** \_\_\_\_\_  
**Specialty:** \_\_\_\_\_ **Physician Office Fax:** \_\_\_\_\_  
**Physician Office Telephone:** \_\_\_\_\_

1. What is the patient's diagnosis?  
 Chronic myeloid leukemia (CML)  
 Acute lymphoblastic leukemia (ALL)  
 Other \_\_\_\_\_
2. What is the ICD-10 code? \_\_\_\_\_
3. Before initiation of therapy, was cytogenetic (conventional or FISH) and/or molecular testing (PCR) performed to detect the Ph chromosome or BCR-ABL gene?  Yes  No
4. Prior to starting therapy, were the cells Philadelphia chromosome positive and/or BCR-ABL positive?  
 Yes  No **ACTION REQUIRED: Attach cytogenetic and/or molecular test results.**
5. Does the patient have T315I-positive CML or T315I-positive Ph+ ALL?  Yes  No  
**ACTION REQUIRED: If Yes, attach mutation test results and skip to next section, if applicable.**
6. Is treatment with ANY other tyrosine kinase inhibitor (e.g., imatinib [Gleevec], nilotinib [Tasigna]), dasatinib [Sprycel], bosutinib [Bosulif]) indicated for this patient?  Yes  No

**Complete the following questions if patient's diagnosis is chronic myeloid leukemia (CML).**

7. Is Iclusig requested for the treatment of post-hematopoietic stem cell transplant relapse CML?  
*If Yes, no further questions.*  Yes  No
8. What is the CML phase?  
 Chronic phase  Accelerated phase  Blast phase *If accelerated or blast phase, no further questions.*
9. Is the patient currently receiving Iclusig?  Yes  No *If No, no further questions.*
10. How long has the patient been receiving Iclusig? \_\_\_\_\_ months *If less than 12 months, no further questions.*
11. Does the patient show evidence of disease progression or unacceptable toxicity?  Yes  No

***I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.***

**X** \_\_\_\_\_  
**Prescriber or Authorized Signature** **Date (mm/dd/yy)**

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Iclusig SGM - 2/2016.

CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst and BlueChoice members.

CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. are both independent licensees of the Blue Cross and Blue Shield Association. The Blue Cross and Blue Shield Names and Symbols are registered trademarks of the Blue Cross and Blue Shield Association. ® Registered trademark of CareFirst of Maryland, Inc.